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1. Introduction 
Blood brain barrier (BBB) disruption is an integral feature of numerous neurological 
diseases with infectious, inflammatory, neoplastic and vascular components. It is of 
particular interest in the immune mediated neurological diseases multiple sclerosis (MS), 
acute disseminated encephalomyelitis (ADEM), and acute hemorrhagic leukoencephalitis 
(AHLE).  In particular, AHLE is associated with very high mortality.  A fundamental 
question in these diseases is the extent inflammatory immune cells contribute to CNS 
vascular permeability.  This lack of understanding currently undermines therapeutic 
approaches to ameliorate uncontrolled BBB disruption.  In this review, we highlight the 
current experimental model systems available to address the contribution of inflammatory 
cells in BBB disruption.  The contribution of T cells and other immune cell subsets in altering 
blood brain barrier tight junctions in the experimental autoimmune encephalomyelitis 
(EAE), lipopolysaccharide (LPS), and virus induced CNS vascular permeability model 
systems is also addressed.   Results obtained from the use of these model systems have put 
forward a defined role for neutrophils, CD4 and CD8 T cells and vascular endothelial 
growth factor (VEGF) in BBB disruption.  Based on these findings, we describe models in 
which immune cells engage and alter CNS cell types of the neurovascular unit and define 
future avenues of research. 
Acute disseminating encephalomyelitis (ADEM) and acute hemorrhagic leukoencephalitis 
(AHLE) are demyelinating diseases that usually present shortly after infections or 
vaccination (Callen et al., 2009; Gibbs et al., 2005). ADEM typically has an overall favorable 
prognosis, with 60-80% of patients showing a complete recovery (Dale et al., 2000; Gibbs et 
al., 2005; Rust, 2000; Tenembaum et al., 2002). AHLE, which is also known as Hurst’s 
disease, has been considered a severe form of ADEM and has a very poor prognosis, usually 
resulting in death in 2-14 days (Geerts et al., 1991; Hart & Earle 1975; Pinto et al., 2011; Posey 
et al., 1994; Suchowersky et al., 1983). This disease is characterized by extensive BBB 
disruption and microhemorrhage formation. Typical acute symptoms of AHLE include 
fever, malaise, and headache, followed by a rapid progression of multifocal neurologic signs 
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(Posey et al., 1994). The MRIs of AHLE patients present with edema, white matter lesions, 
and petechial hemorrhage (Gibbs et al., 2005; Fugate et al., 2010; Pinto et al., 2011). 
Neutrophilic leukocytosis in the CSF has also been shown in cases of AHLE. (Pinto et al., 
2011). Usually, the patient’s level of consciousness progressively declines, resulting in coma 
(Posey et al., 1994). AHLE progresses rapidly, causing an accelerated deterioration of the 
patient. This coupled with its close resemblance to herpes simplex encephalitis (HSVE) may 
cause this disease to be under diagnosed in addition to demonstrating a probably viral 
etiology to AHLE (Gibbs et al., 2005). Furthermore, recent clinical cases have shown that this 
commonly fatal disease may also result from severe H1N1 influenza infection (Fugate et al., 
2010; Wang, G., et al., 2010) and Epstein-Barr virus (Befort et al., 2010). 
There are currently no standard treatments for ADEM or AHLE, and the etiology of these 
two disorders is still not well understood. Several studies have demonstrated that the 
neurovascular unit (NVU), which is composed of cerebral endothelial cells (CECs) 
surrounded by astrocytes, pericytes, axonal endings, and microglia (Begley, 2004), may 
ultimately control permeability of the BBB through tight junctions between CECs of the 
vasculature. These tight junctions are composed of the proteins occludin and claudin, which 
seem to provide the primary seal of the tight junction, JAMs, which may play a role in 
monocyte and leukocyte adhesion, (Ballabh et al., 2004; Hawkins & Davis 2005) and the 
zona-occludin proteins, which provide the stability for the formation of tight junctions (Lai 
et al., 2005). However, the extent inflammatory immune cells contribute to the alteration of 
the NVU to a permeable state remains largely undefined. This relative lack of knowledge 
currently undermines effective therapies to treat diseases characterized by uncontrolled 
disruption of the BBB. Therefore, it is essential for the role of immune cells to be investigated 
in experimental mouse models, including experimental autoimmune encephalomyelitis 
(EAE), lipopolysaccharide (LPS), and virus induced CNS vascular permeability model 
systems, including the lymphocytic choriomeningitis virus (LCMV) and the peptide 
induced fatal syndrome (PIFS) models. These models may lead to the development of 
effective therapeutic approaches for these devastating diseases.  
2. The Concept of the Blood Brain Barrier (BBB) 
Before delving into how the BBB can be altered by immune cells, contributing to a variety of 
neurological diseases, it is important to understand the basic concept of the BBB and how 
different molecules gain access to it. The BBB is a highly specialized brain endothelial 
structure that plays a role in separating components of the circulating blood from neurons 
(Zlokovic, 2008). It is important to note that diffusion of soluble factors in the blood is 
controlled by capillaries, which contain specialized tight junctions. Meanwhile, recruitment 
of immune cells takes place at postcapillary venules (Bechmann et al., 2007). While an intact 
BBB is essential, it is also important that certain blood derived factors, such as nutrients, be 
able to cross this barrier. This is achieved through transcellular transport systems, including 
carrier-mediated, ion, active efflux, receptor-mediated, and caveolae-mediated transport. 
Carrier-mediated transport allows the transport of essential nutrients such as glucose to 
meet the metabolic needs of the brain. Ion transporters such as the sodium pump are 
important in order to meet energy demands. Active efflux of molecules from the brain 
endothelium is important for rapid removal of harmful substances such as ingested toxic 
lipophilic metabolites. Receptor-mediated transport systems have played an important role 
as targets for drug delivery to the brain. Caveolae, a special type of lipid raft, contributes to 
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transcellular permeability by regulating endocytosis and transcytosis (Zlokovic, 2008). 
Therefore, the BBB has multiple mechanisms by which blood derived agents could enter the 
CNS. In this review, we will focus on the role of immune-mediated alterations of the 
neurovascular unit and the subsequent alterations in vascular endothelial cell tight 
junctions. 
3. Organization of the Neurovascular Unit 
The vascular permeability observed in ADEM and AHLE has generated a central question 
of how inflammation promotes alteration of the BBB.  The BBB has unique features that 
enable it to create a solute impermeable barrier (Begley 2004).  Based on electron microscopy 
data, the current model of the BBB is composed of CNS vasculature consisting of 
interlocking cerebral endothelial cells (CECs).  Surrounding CECs are astrocytes, pericytes, 
axonal endings, and microglia (Begley 2004).  Collectively, this group of cells is referred to 
as the neurovascular unit (NVU).  Several recent models of BBB disruption place the NVU as 
a dynamic interacting multicellular network that ultimately controls permeability of the BBB 
(Begley, 2004; Minagar & Alexander, 2003; Zlokovic, 2008). Specific properties of each NVU 
cell type in maintaining BBB integrity are described below and depicted in Figure 1. 
3.1 Cerebral Endothelial Cells (CECs) 
CECs form tight junctions with one another, creating microvasculature that serves as a seal 
between the blood and CNS tissue (Fanning et al., 1999; Itoh et al., 1999; Tsukita et al., 1999; 
Wolburg & Lippoldt 2002). While these tight junctions are considered the actual gate of the 
BBB, it is thought that CECs alter tight junctions following signaling from other cells of the 
NVU (Demeuse et al., 2002; Marchi et al., 2009). Numerous in vitro and in vivo studies have 
demonstrated that CECs only form blood brain barrier properties if they are in the presence 
of astrocytes or astrocyte-derived factors (Hayashi et al., 1997; Janzer & Raff, 1987; Maxwell 
et al., 1987; Neuhaus et al., 1991; Sobue et al. 1999). 
3.2 Astrocytes 
Greater than 90% of the albuminal surface of CECs are in direct contact with astrocytes 
(Abbott, 2002; Demeuse, et al., 2002). Astrocytes have been shown in vitro to promote the 
opening and maintenance of CEC tight junctions upon stimulation (Schroeter et al., 2001; 
Siddharthan et al., 2007; Smith, 2007). For this reason, it is hypothesized that astrocytes play 
a critical role in maintaining CEC integrity through direct contact and chemical messengers 
in vivo (Abbott, 2005; Abbott et al., 2006; Haseloff et al., 2005). In addition, astrocytes form 
complex networks with vasculature, potentially communicating through endfeet and Ca2+ 
waves (Koehler et al., 2006). Their close association with CECs and their role in BBB 
formation make astrocytes a potential candidate NVU cell type involved in altering vascular 
permeability.  
3.3 Pericytes 
Pericytes have been found to promote tighter BBB formation and reduced transendothelial 
resistance in vitro (Dohgu et al., 2005; Ramsauer, et al., 2002). Pericytes are also an important 
source of TGF- in CEC microvessel formation (Dohgu et al., 2005). Transgenic approaches 
to inhibit migration of pericytes to vasculature through selective disruption of PDGF- in 
CECs results in susceptibility to vascular permeability and edema (Hellstrom et al., 2001). 
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This evidence, while indirect, suggests a potential role for pericytes in maintaining CEC BBB 
stability in vivo. 
3.4 Neurons 
Neurons have been implicated in CNS vascular permeability due to the close proximity of 
axonal endings with astrocyte endfeet and CECs (Hamel, 2006). Neuronal activity could 
therefore communicate with astrocytes which are in direct contact with CECs.  Specific 
subpopulations of cortical GABAergic interneurons have been demonstrated to promote 
vasodilation through close association with astrocyte endfeet (Cauli et al., 2004). 
Furthermore, neurons express high levels of nitric oxide and COX-2, implying a potential 
mechanism to signal alteration of smooth muscle near vasculature (Vidensky et al., 2003). 
These observations suggest a potential mechanism for neurons to regulate CEC function in a 
process dependent or independent of astrocytes.  
 
 
Fig. 1. A model depicting the organization of the neurovascular unit (NVU). The NVU is 
composed of cerebral endothelial cells (CECs) surrounded by astrocytes, pericytes, axonal 
endings, and microglia. The NVU may ultimately control permeability of the BBB through 
tight junctions between CECs of the vasculature. 
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3.5 Microglia 
Microglia have been implicated as mediators of CNS vascular permeability due to their 
expression of proinflammatory cytokines that promote BBB disruption in vitro, the most 
notable being TNF- (Zhao et al., 2007). Microglia are potent antigen-presenting cells of the 
CNS that express both class I and class II molecules.  Ex vivo isolated microglia have also 
been demonstrated to activate T cells in vitro (Mack et al., 2003). Therefore, microglia have 
the capacity to both interact with T cells and express proinflammatory factors that could 
alter the NVU resulting in BBB disruption. 
4. Cerebral endothelial cell tight junctions and CNS vascular permeability 
The NVU has been implicated in controlling entry of blood derived products across the BBB 
through tight junctions between CECs of the vasculature. Tight junctions are composed of 
both cytoplasmic and transmembrane proteins. These proteins are linked to an actin-based 
cytoskeleton allowing for a tight seal among cerebral endothelial cells of CNS vasculature 
(Petty & Lo, 2002). Cytoplasmic proteins collectively referred to as the Membrane-
Associated Guanylate Kinase-Like homolog family provide structural support and play an 
organizational role for CECs (Hawkins & Davis, 2005). The current model of how the 
transmembrane proteins occludin, claudin and junctional adhesion molecules (JAMs) 
present in tight junctions interact is shown in Figure 2. Among these proteins, occludin and 
claudin appear to form the primary seal of the tight junction, whereas JAMs are proposed to  
 
 
Fig. 2. Molecular model of tight junctions between cerebral endothelial cells (CECs). 
Occludins, claudins and junctional adhesion molecules (JAMs) regulate adhesion of CECs. 
Occludins and claudins adhere to the zona occludin complex which consists of an 
interaction of ZO-1, ZO-2, and ZO-3 proteins. In contrast JAMs adhere only to zona 
occludin-1 (ZO-1). The zona occludin proteins in turn adhere to actin cytoskeleton proteins. 
Opening of tight junctions during inflammation appears to be an orchestrated event of 
degradation and expression of occludins and claudins, respectively and contraction of actin 
cytoskeleton. Model is modified from (Minagar & Alexander, 2003). 
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be involved in monocyte and leukocyte adhesion and transmigration through the BBB 
(Ballabh et al., 2004; Brooks et al., 2005). The zona-occludin proteins, ZO-1, ZO-2 and ZO-3, 
have been shown to connect the transmembrane proteins to actin, providing stability for 
tight junction formation (Lai, 2005). Expression of occludin is much higher in neural 
endothelial cells when compared to peripheral endothelial cells whereas claudins are found 
in both (Ballabh et al., 2004). Occludin could therefore contribute to structural differences in 
BBB tight junctions as compared to tight junctions found in peripheral tissue.  
Following insult to the CNS, inflammatory immune cells home to the CNS tissue. Despite 
the ability of immune cells to enter the CNS, the BBB remains relatively impermeable to 
other blood derived products. This is potentially due to immune cells entering the CNS 
without opening tight junctions between CECs via post capillary venules (Bechmann et al., 
2007; Burns et al., 2000; Wolburg et al., 2005). However, tight junctions do not remain closed 
in all cases of CNS inflammation. Some instances of CNS inflammation promote opening of 
tight junctions and increased permeability of blood derived products through the BBB. Why 
tight junctions and the BBB open under some inflammatory circumstances but not others 
remains unknown. Current models suggest inflammatory immune cells promote opening of 
tight junctions between CECs through the activation of cells that line the BBB (Minagar & 
Alexander, 2003; Zlokovic, 2008). Chemokine and cytokine emission from immune cells 
have been implicated in this process with some examples being VEGF, IFN-, TNF-, IL-1 
and IL-6 (Argaw et al., 2009; Blamire et al., 2000; Didier et al., 2003; Ferrari et al., 2004; 
Krizanac-Bengez, et al., 2003; Laflamme, 1999; Paul et al., 2003; Stoll et al., 2000; Suidan et al., 
2010; Wong et al., 2004). Chemokines enable adhesion of immune cells by mediating the 
activation of integrins on these cells. Additional signals lead to cytoskeletal reorganization, 
permitting transmigration of immune cells across the BBB, which is directed by matrix 
metalloproteinases (MMPs). Current therapies focus on blocking the integrins, which have 
resulted in reductions of BBB breakdown in patients with active multiple sclerosis. 
Targeting MMPs may also serve to stabilize BBB dysfunction (Zlokovic, 2008). 
5. Importance of vascular endothelial growth factor (VEGF) in promoting CNS 
vascular permeability   
Clinical observations and current experimental model systems used to address the 
contribution of inflammatory cells in BBB disruption have put forth a potential role for 
VEGF, a cytokine that has an instrumental role in vascular development and angiogenesis 
(Deininger et al., 2003; Karamysheva, 2008; Olsson et al., 2006; Su et al., 2006).  However, 
VEGF was originally defined as “vascular permeability factor” which was found to be 
secreted by tumor cells (Senger et al., 1983). VEGF is over 50,000 fold more potent than 
histamine in promoting vascular permeability in in vitro assays, demonstrating the potency 
of this cytokine to promote deregulation of the vasculature (Shulman et al., 1996). VEGF 
mediated permeability occurs through modification of endothelial cells to develop (a) 
vesiculo-vacuolar organelles, (b) increased caveolae formation, (c) fenestrations in 
membranes, and (d) alteration of tight junctions (Antonetti et al., 1999; Esser et al., 1998; 
Feng et al., 1999; Roberts & Palade, 1995). These modifications in endothelial cells could 
result in different levels of vascular permeability that range from the entry of small particles 
up to whole erythrocytes (Weis & Cheresh, 2005). The prevailing hypothesis is that VEGF’s 
effects on endothelial cells of vasculature result in local edema, hemorrhage and tissue 
damage (Chi et al., 2005). However, the specific interactions between inflammatory cells that 
result in VEGF-mediated vascular permeability remain a developing area of research.    
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The role of VEGF in the CNS is further complicated by the dual role of this cytokine in both 
angiogenesis and development, as well as in mediating vascular permeability. VEGF-
deficient mice are an embryonic lethal phenotype which fail to develop normal vasculature 
(Carmeliet et al., 1996; Ferrara et al., 1996). Adding to the complexity of VEGF in the CNS is 
the rather ubiquitous nature of VEGF expression.  During the onset of neuropathology, 
several CNS cell types including astrocytes, neurons and microglia have been reported to 
upregulate VEGF expression (Hayashi et al., 1997; Issa et al., 1999; Marti & Risau, 1998; Plate 
et al., 1999). Meanwhile, the CNS cell types that express the VEGF receptors, Flt-1 and Flk-1, 
include endothelial cells, smooth muscles and neurons (Carmeliet & Storkebaum, 2002; 
Ishida et al., 2001). VEGF is expressed in the CNS within 6 hours following a stroke and this 
cytokine has also been localized to MS lesions (Marti et al., 2000; Proescholdt et al., 2002). In 
experimental rodent models of hypoxia, VEGF expression in the CNS increases with the 
incidence of vascular permeability. Blocking VEGF in this model resulted in reduced 
vascular permeability (Schoch et al., 2002). Therefore, there is significant evidence in the 
literature that VEGF may be a viable target to treat neurological diseases characterized by 
vascular permeability and hemorrhage.  
6. Tight junction alterations in the Experimental Autoimmune 
Encephalomyelitis (EAE) model 
Experimental autoimmune encephalomyelitis (EAE) is an animal model used to study brain 
inflammation, and its clinical and pathological characteristics closely resemble those of 
ADEM. Induction of EAE produces neurological deficits, inflammatory CNS lesions, and 
disruption of the BBB (Morgan, Shah et al. 2007). This demyelinating disease of the CNS is 
induced by immunizing mice with well characterized myelin peptides, such as PLP, MAG, 
or myelin oligodendrocyte glycoprotein (MOG)35-55 peptide in complete Freund’s adjuvant 
(CFA), which causes inflammatory responses to the protein/peptide. It is also common to 
co-inject the mice with pertussis toxin to break down the blood brain barrier (BBB), allowing 
immune cells to gain access to the CNS tissue (Chen & Brosnan, 2006; Gurfein et al., 2009). 
The use of this mouse model has revealed the role that VEGF, CD4 T cells, astrocytes, tight 
junction proteins, and certain cytokines, such as IL-17, IL-22, and IFN-Ǆ, have in the 
breakdown of the BBB. 
Although IFN-Ǆ was originally believed to play a pathogenic role in EAE, evidence has 
emerged that this cytokine may actually play a suppressive role. Since EAE in general is 
mediated by CD4 T cells, the proliferation and apoptosis of these cells in IFN-Ǆ-deficient 
mice was investigated in order to define the role of IFN-Ǆ in EAE. It was discovered that in 
the absence of IFN-Ǆ, activated CD4 T cells exhibited a more extensive proliferation as well 
as decreased apoptosis when compared to wild-type mice. Therefore, it appears that IFN-Ǆ 
is essential to limit the extent of EAE by serving to suppress the expansion of activated CD4 
T cells (Chen & Brosnan, 2006). 
Argaw et al (2009) have employed the MOG peptide induced EAE model to investigate the 
potential links between the reactivity of astrocytes and BBB disruption. Through the use of 
confocal imaging, they have shown that astrocyte-derived VEGF-A causes down-regulation 
and disruption of the tight junction proteins claudin-5 and occludin, promoting breakdown 
of the BBB, as shown in Figure 3 (Argaw et al., 2009). 
Morgan et al took a closer look at occludin and the signaling events that occur during EAE 
through analysis of spinal cord tissue of naïve and EAE animals. Neurological impairment  
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Fig. 3. (A) VEGF down-regulates claudin-5 and occludin in human BMVECs. Confocal 
imaging of human BMVEC treated with 100 ng/mL VEGF-A for 24 hours and 
immunostained for claudin-5 and occludin. In controls, both proteins localize to the plasma 
membrane in areas of cell-cell contact. Note that claudin-5 and occludin are both down-
regulated by VEGF-A. Data are representative of at least 3 separate experiments on 3 
distinct cultures. (B) Sections of cerebral cortex from 12-week adult C57BL/6 mice 24 h 
following stereotactic microinjection of murine VEGF165 (60 ng in 3 μl PBS/BSA) or vehicle 
control. Sections are immunostained for claudin-5 (red channel) plus fibrinogen (green 
channel). Note that BBB permeability is observed around vessels in VEGF-injected areas. (C) 
Immunoreactivity for claudin-5 and occludin appears patchy and discontinuous in VEGF-
injected areas. (Scale bars: A, 20 μm; B, 75 μm; C,  20 μm.) Data shown in B and C are 
representative of findings from at least 4 mice per time point per condition. (This figure was 
reproduced from Argaw, A. T., B. T. Gurfein, et al. (2009). VEGF-mediated disruption of 
endothelial CLN-5 promotes blood-brain barrier breakdown. Proceedings of the National 
Academy of Sciences of the United States of America 106(6): 1977-1982. Permission was granted 
by PNAS). 
was observed in the animals undergoing EAE, which demonstrated a progressive 
development of tail and hind limb weakness and eventually became paraplegic. 
Immunohistochemical analysis of tissue revealed an increase in the number of nuclei 
through Hoechst staining and the presence of infiltrated macrophages and activated 
microglia through ED1 labeling in animals treated with EAE, thus confirming the 
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inflammatory nature of the disease. Additionally, an increase in the abundance of the 
plasma proteins albumin and transferrin was observed in EAE tissue, which is also 
consistent with inflammation leading to BBB breakdown. Immunoprecipitation revealed 
increased electrophoretic mobility of occludin in EAE animals which was found to be a 
result of occludin dephosphorylation. This was confirmed through the use of phosphatase 
treatment, which caused a further increase in electrophoretic mobility, while phosphatase 
inhibitors blocked this effect. These changes in occludin phosphorylation may signal 
changes in permeability of tight junctions. Furthermore, localization of occludin was 
analyzed via immunohistochemistry and was observed at intercellular junctions in naïve 
tissue, which is consistent with previous findings. However, localization of occludin to 
intercellular junctions in EAE tissue was often not apparent. Junctionally-localized claudin-5 
was also disrupted in EAE tissue, indicating that the structure of tight junctions is disrupted 
in EAE. These findings reveal a potential role for occludin in BBB disruption (Morgan et al., 
2007). Therefore, further investigation of this tight junction protein, along with its 
phosphorylation changes and signaling pathways, may open the door to new potential 
therapeutics for diseases involving breakdown of the BBB. 
In addition to claudin-5 and occludin, the tight junction adaptor protein ZO-1 has also been 
analyzed using the EAE model. CNS tissue from naïve and EAE animals was analyzed for 
expression of ZO-1. Immunohistochemistry and confocal microscopy revealed disrupted 
expression of ZO-1 in lesion areas of EAE animals when compared to naïve animals. In 
order to correlate this disruption with clinical symptoms, time-course studies of ZO-1 
distribution were performed. It was found that disruption of ZO-1 preceded clinical disease 
in EAE in lesion areas and correlated with symptomatic clinical signs in non-lesion areas. 
Additionally, vascular permeability was analyzed through the use of Evans blue dye, and 
an increase in permeability was found at the peak of EAE. Taken together, it is evident that a 
complete understanding of the regulation of tight junction architecture is essential for the 
development of therapies (Bennett et al., 2010). 
Kebir et al employed the EAE model to examine the effects of Th17 lymphocytes, which are 
known to have encephalitogenic potential, on BBB disruption, and found that significantly 
more Th17 lymphocytes migrated across the BBB in vitro than did either Th1 or ex vivo CD4+ 
lymphocytes. To confirm the ability of these lymphocytes to cross the BBB in vitro, cells were 
stained for IL-17 and IL-22, a cytokine product of Th17 cells, before and after migration. 
There was a significant increase in IL-17+ and IL-22+ lymphocytes after migration. 
Furthermore, it was found that both IL-17 and IL-22-producing lymphocytes expressed the 
cytolytic molecule granzyme B, enabling these cells to kill human fetal neuron-enriched 
cultures. Similar to the previously mentioned studies, the effect on tight junctions was also 
investigated. It was discovered that treating monolayers of human BBB-ECs with IL-17 
produced an increase in the diffusion of fluorescently-labeled BSA, which coincided with a 
decrease in occludin and ZO-1 expression in EAE mice. Additionally, it was found that Th17 
lymphocytes contribute to inflammation through the recruitment of CD4+ lymphocytes 
(Kebir et al., 2007). 
The mechanisms of IL-17-induced BBB disruption were further investigated using the EAE 
model by Huppert et al. It was discovered that IL-17 treatment disrupted tight junction 
molecules by decreasing occludin levels and causing a reorganization of ZO-1, thus 
impairing BBB integrity. It was also found that IL-17 induced an increase in reactive oxygen 
species (ROS) formation, a mechanism known to be involved in BBB disruption. To link this 
observation to the effect on tight junctions, the involvement of ROS signaling was 
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investigated, and DPI, an NAD(P)H oxidase inhibitor, was found to prevent the effect of IL-
17 on occludin. Additionally, it has been demonstrated that phosphorylation of myosin light 
chain (MLC) in BECs is induced by IL-17, leading to BBB permeability. When EAE mice 
were treated with ML-7, a MLCK inhibitor, they developed significantly milder clinical 
signs and had a reduced number of infiltrating lymphocytes and macrophages when 
compared with vehicle-treated mice. This treatment also reduced the levels of IL-17 and IL-
22, which are pathogenic cytokines associated with EAE. Furthermore, IL-17-deficient mice 
portrayed lower levels of oxidative stress and were protected from BBB disruption induced 
by EAE (Huppert et al., 2010). Taken together, these two studies portray a role for 
proinflammatory cytokines, particularly IL-17, on the integrity of the BBB. Targeting the 
mechanisms of these cytokines could bring about novel therapeutic strategies for 
inflammatory diseases such as ADEM and AHLE. The results from these studies can be 
incorporated into a model, which is shown in Figure 4. 
 
 
 
Fig. 4. Mechanisms of CD4 T cell initiated BBB disruption. (A) Th17 lymphocytes contribute 
to inflammation through IL-17, which induces NAD(P)H oxidase-dependent ROS 
formation, leading to phosphorylation of MLC, and subsequent BBB permeability. (B) 
Additionally, CD4 T cells induce astrocytes to release VEGF, causing down-regulation of the 
tight junction proteins claudin-5 and occludin, which promotes breakdown of the BBB. 
7. Lipopolysaccharide (LPS) model 
Injection of small amounts of lipopolysaccharide (LPS), a component of the cell wall of 
Gram-negative bacteria, can induce shock and systemic inflammation. The signaling 
pathway begins by LPS binding to LPS binding protein (LBP), with subsequent transfer of 
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LPS to CD14. In order for the proper targeting of TLR-4 to the surface and its ability to 
recognize LPS, MD-2 binds to TLR-4. This complex then interacts with CD14:LPS, sending a 
signal that activates the transcription factor NFkB, which activates genes that encode 
proteins that play a role in defense against infection. 
Qin et al sought to understand the effects of systemic LPS on brain inflammation. Upon 
peripheral injection of LPS, there was a rapid increase in the cytotoxic factor TNFǂ, which 
remained elevated in the brain even 10 months after treatment. Injection of LPS also 
promoted the activation of brain microglia through TNFǂ receptors. Brain sections were 
immunostained with Iba1, an antibody specific for microglia. Increased cell size, irregular 
shape, and intensified Iba1 staining are apparent in LPS-treated mice when compared with 
controls. This activated microglia may lead to the production of more inflammatory factors, 
which could possibly lead to neuronal death. This reactive microgliosis may be the cause of 
progressive and chronic neuroinflammation (Crews et al., 2007). 
Using a similar model, Brooks et al employed Complete Freund’s adjuvant (CFA), which 
has also been known to stimulate the production of TNF. It was discovered that changes in 
certain transmembrane tight junction proteins alter the function of the BBB. For example, 
occludin was significantly decreased in CFA-injected rats, while claudin-3 and claudin-5 
were both significantly increased when compared to saline-treated controls. The alteration 
of these tight junction protein levels coincided with BBB disruption (Brooks et al., 2005). 
Matrix metalloproteinases (MMPs) mediate BBB disruption and trafficking of immune cells 
into the CNS and can be induced by LPS. It has previously been shown that expression of 
stromelysin-1 (MMP-3) occurs after intracerebral injection of LPS. To investigate the effect of 
MMP-3 on BBB disruption, MMP-3 knockout mice have been used. LPS injection increased 
CNS vascular permeability in wild-type mice but not in mice lacking MMP-3. Additionally, 
quantitative stereology showed that MMP-3 KO mice exhibited a significant reduction in 
neutrophil infiltration. Furthermore, when analyzing alterations in tight junction proteins, it 
was discovered that both claudin-5 and occludin were decreased after LPS injection in both 
WT and MMP-3 KO mice. However, there was less tight junction damage in the mice 
lacking MMP-3. Therefore, further investigating the mechanisms of MMP-3 activity may aid 
in the development of MMP inhibitors to be used in the treatment of neuroinflammatory 
diseases (Gurney et al., 2006). Importantly, this model system illustrates the potential of 
peripheral inflammation to induce microglia activation and subsequent BBB disruption in 
the CNS, the tentative model of which is put forward in Figure 5. 
8. LCMV model of Vascular Permeability: Lymphocytic Choriomeningitis 
Virus (LCMV) 
Lymphocytic choriomeningitis virus (LCMV) is a well-studied fatal model of CNS vascular 
permeability. CD8+ T cells are important mediators in the response to several viral 
infections. These immune cells are activated in secondary lymphoid organs, particularly the 
spleen, and then migrate to sites of infection, where they kill virus-infected cells and secrete 
pro-inflammatory cytokines such as IFN-Ǆ and TNF-ǂ. It has previously been shown that 
the immunopathology resulting from CNS infection with LCMV correlates with the 
cytotoxic activity of virus-specific CD8+ T cells and this process is perforin-dependent (Kagi 
et al., 1994). Storm et al sought to re-evaluate the role of perforin in this process. They 
discovered that perforin-deficient mice infected with LCMV still die from inflammation 
mediated by CD8+ T cells, although this death is delayed 2-5 days when compared to wild-
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type mice infected with LCMV. Nevertheless, death occurred despite the absence of 
perforin, impaired pro-inflammatory cytokine production, and a deficit in the cytotoxic 
ability of CD8+ T cells. However, it was also shown that CD8+ T cells were required for the 
lethality, because those that received CD8-depleting antibodies survived. The delay in 
fatality in the absence of perforin may be attributed to virus-specific T cells being prevented 
from entering the CNS. Additionally, these T cells may not be effectively recruited to the 
CNS within the first 6-7 days after infection. However, once they are able to enter the CNS, 
they have the ability to induce fatal CNS pathology (Storm et al., 2006). 
 
 
Fig. 5. Proposed model of LPS-induced systemic inflammation that results in BBB 
disruption. LPS binds to TLR-4, promoting shock and systemic inflammation that leads to 
BBB disruption. LPS causes an increase in TNFǂ, causing reactive microgliosis and chronic 
neuroinflammation. Additionally, tight junction proteins are altered, coinciding with BBB 
disruption. 
Similarly, Kim et al, using the LCMV model, employed two-photon microscopy to visualize 
the dynamics of immune cells in the meninges. They observed motile CTL which expressed 
chemoattractants that recruited myelomonocytic cells, such as neutrophils. Therefore, it was 
inferred that a disorder that depends on CD8+ T cells may rely solely on CTL recruited 
myelomonocytic cells. Using mice with single mutations in all major CTL effector pathways, 
including perforin and TNF-ǂ, it was found that mice still experienced convulsive seizures 
after LCMV infection. Therefore, no single deficiency had the ability to prevent disease. This 
group then questioned the potential role for monocytes and/or neutrophils in the seizure-
induced death on day 6. To investigate this, they depleted both monocytes and neutrophils 
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by administering high-dose anti-GR-1 to CCR2 knockout mice. This treatment extended 
survival by 3 days and preserved vascular integrity on day 6, as evidenced by leakage of 
Evans blue dye into the brain. Therefore, they concluded that CD8+ T cells may primarily 
serve to attract other effector populations. Potential therapies could involve reduction of 
myelomonocytic activation or targeting the CTL chemotactic mechanisms that recruit 
myelomonocytic cells (Kim et al., 2009). 
Another study addressing LCMV-mediated death once again showed the importance of 
CD8+ T cells in generating the lethality of the disease. This study showed that CD8-deficient 
mice survived after i.c. injection of LCMV. Additionally, they showed that RAG knockout 
mice, which lack T and B cells, do not exhibit morbidity or mortality, thus providing 
evidence attributing these effects to immunopathology instead of viral damage. This group 
also addressed a possible connection between BBB disruption and LCMV pathogenesis 
through the use of Evans blue staining. While leakage of Evans blue dye was observed in 
C57BL/6 mice on day 5, before the onset of seizures, RAG knockout mice did not show 
signs of BBB disruption, indicating that BBB damage is induced by adaptive immunity. The 
role of perforin was also addressed in this study, with perforin knockout mice showing an 
intermediate phenotype after LCMV challenge and no clinical signs of the disease. 
However, surviving perforin knockout mice showed an increase in BBB disruption similar 
to C57BL/6 mice. Therefore, although BBB disruption occurs after LCMV infection, it may 
not be associated with mortality. This group proposed that other neuroanatomical changes, 
such as brain herniation, may be the most likely cause of mortality. Understanding the basis 
of LCMV neuropathogenesis may be helpful for designing therapies for viral hemorrhagic 
fevers in addition to ADEM and AHLE (Matullo et al., 2010). 
9. Inducible model of severe vascular permeability: Peptide-Induced Fatal 
Syndrome (PIFS) 
The Daniel’s strain of Theiler’s murine encephalomyelitis virus (TMEV) is a murine 
picornavirus that causes a transient early meningoencephalitis in all mouse strains, and 
persistent infection of the white matter with demyelination in susceptible strains (Njenga et 
al., 1997; Rodriguez & David, 1985; Rodriguez, 1986). During acute TMEV infection, mice of 
H-2b haplotype mount an antiviral CD8 T cell response that is highly focused on an 
immunodominant TMEV peptide, VP2121-130, presented in the context of the Db class I 
molecule (Johnson et al., 1999; Johnson et al., 2001). It was demonstrated that intravenous 
injection of this VP2121-130 peptide prior to TMEV infection inhibited VP2 peptide specific 
CD8 T cell expansion in the CNS and prevented IFN- receptor-/- mice from developing 
paralytic disease. However, injection of VP2 peptide during acute TMEV infection, after the 
expansion of Db:VP2121-130 epitope specific CD8 T cells in the CNS, resulted in death in 24 to 
48 hours. It was determined that this fatal syndrome was antigen specific, because mice 
were asymptomatic when given the mock control Db binding E7 peptide. In subsequent 
studies, our laboratory determined that CNS vascular permeability and hemorrhage are a 
major component of this condition. This peptide induced fatal syndrome (PIFS) is a readily 
reproducible means to investigate CD8 T cell-mediated CNS vascular permeability (Figure 
6). The major advantage of this model system is that BBB disruption is inducible through 
administration of the antigenic VP2 peptide, enabling a kinetic analysis of early and late 
cellular and gene expression events. While BBB disruption is a common feature of numerous 
neurological conditions, the PIFS model with its high level of CNS vascular permeability, 
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edema, rapid demyelination, and onset of multiple focal hemorrhages, most closely 
resembles AHLE (Figure 7). 
 
 
Fig. 6. Mouse model of CNS vascular permeability. CD8+ T cell-mediated vascular 
permeability is induced in C57BL/6 mice. Mice are intracranially infected with TMEV at day 
0. During the peak of CD8 T cell expansion, mice are intravenously administered VP2121-130 
peptide to induce permeability or E7 control peptide. The CNS is harvested on the following 
day.  
In addition to being mediated by antigen-specific CD8+ T cells, PIFS is influenced by 
perforin expression and genetic background. C57BL/6 perforin-deficient mice are resistant 
to this fatal syndrome. Another key determinant in the development of PIFS is the genetic 
background of the animal. While C57BL/6 mice are highly susceptible to PIFS, both FVB 
and 129 SvIm strains are significantly more resistant. Interestingly, this holds true despite 
these strains having a substantial population of antigen-specific CD8+ T cells (Johnson et al., 
2005). 
Another important aspect of the PIFS model is the observation that mice lacking major 
histocompatibility complex (MHC) class II, and thus CD4 T cells, IFN-ǄR, TNF-ǂ, TNFR1, 
TNFR2, and TNFR1/TNFR2 still succumbed to the fatal syndrome. Inhibiting interleukin-1 
and lymphotoxin-ǃ did not serve to protect the mice from PIFS (Johnson et al., 2005). 
Therefore, it appears that the cytokines and CD4 T cell subsets heavily studied in other 
model systems of immune-mediated CNS vascular permeability do not play a role in the 
development of fatal blood brain barrier disruption in the PIFS model. However, removal of 
antigen-specific CD8+ T cells conferred protection, preventing mice from becoming 
moribund (Johnson et al., 2005). Suidan et al took this into consideration and investigated 
the contribution of the effector functions of CD8+ T cells, notably perforin and FasL, on 
disruption of the BBB and PIFS. It was first observed that the expansion of CNS infiltrating 
antigen-specific CD8+ T cells was not significantly different between C57BL/6 mice and 
C57BL/6 mice deficient in perforin or FasL. MRI analysis revealed that while C57BL/6 and 
C57BL/6 FasL deficient mice both exhibited extensive vascular permeability, mice lacking  
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Fig. 7. In vivo MRI images of 8 day TMEV infected C57BL/6 mice, 24 hours after VP2121–
130 peptide injection (right panel) or irrelevant E7 peptide injection (left panel). Top row: 
axial images extracted from the gadolinium enhanced T1 weighted dataset demonstrate 
extensive contrast enhancement of confluent areas of the brain in the VP2 injected mouse, 
and very faint enhancement in the parahippocampal area in the E7 injected animal. 
Middle row: T2 weighted images demonstrate T2 hyperintensities, corresponding with 
areas of edema, inflammatory infiltrates, demyelination and tissue damage in the VP2 
injected mouse; minimal hyperintense changes are also demonstrated in the 
parahippocampal areas of the E7 injected animal. Bottom row: T2* weighted images 
demonstrate punctuate T2 hypointensities, corresponding with areas of 
microhemorrhages in the VP2 injected mouse. (Reproduced with permission from Pirko, 
I., G. L. Suidan, et al. (2008). Acute hemorrhagic demyelination in a murine model of 
multiple sclerosis. Journal of neuroinflammation 5: 31). 
perforin were protected. These same results were obtained when employing the FITC 
permeability assay, in which FITC-albumin is intravenously given to VP2 or E7 treated mice. 
Since albumin does not readily cross the BBB under normal conditions, this technique 
enables analysis of CNS vascular permeability with both microscopy and analysis of brain 
homogenate on an immunofluorescent plate reader. The combination of these two 
techniques, in addition to T1 gadolinium enhanced, T2 and T2* MRI, revealed that perforin, 
but not FasL, is essential for VP2 peptide induced CNS vascular permeability, edema and 
microhemorrhage formation, respectively. It was also found that astrocyte activation as 
measured by GFAP expression is dependent on perforin expression (Figure 8). High-
resolution microscopy revealed the expression of GFAP co-localized with FITC-albumin 
leakage. This is important because astrocytes have been shown to be involved in regulation 
of BBB integrity (Suidan et al., 2008).  
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Fig. 8. Vascular permeability and astrocyte activation following administration of VP2121–130 
peptide is dependent on perforin expression. Tissue sections obtained from the brains of 
each animal were analyzed for astrocyte activation and vascular permeability as measured 
by leakage of FITC albumin into the CNS and expression of GFAP. Shown is GFAP 
expression and the extent of FITC-albumin leakage in the striatum of E7 control or VP2121–130 
peptide administered animals. Animals represented are (A) C57BL/6, E7 treatment, 5x, (B) 
C57BL/6, E7 treatment, 63x, (C) C57BL/6, VP2121–130 treatment, 5x, (D) C57BL/6, VP2121–130 
treatment, 63x, (E) C57BL/6 Prf-/-, E7 treatment, 5x, (F) C57BL/6 Prf-/-, E7 treatment, 63x, 
(G) C57BL/6 Prf-/-, VP2121–130 treatment, 5x, (H) C57BL/6 Prf-/-, VP2121–130 treatment, 63x. 
(This figure was reproduced from Suidan, G. L., J. R. McDole, et al. (2008). Induction of 
blood brain barrier tight junction protein alterations by CD8 T cells. PloS one 3(8): e3037). 
Time course experiments have been conducted in order to determine the sequence of events 
that occur in the development of PIFS. It was discovered that astrocyte activation and 
degradation of the tight junction protein occludin occur prior to peak levels of CNS vascular 
permeability and motor deficits. In accordance with the results from the LPS model 
employed by Brooks et al using the same microvessel isolation technique, it was found that 
expression of claudin-5 was significantly increased, while expression of occludin was 
significantly decreased. In both the LPS and the PIFS model, these alterations of tight 
junction protein levels coincide with BBB disruption. Furthermore, in the PIFS model, 
concurrent with a lack of vascular permeability, tight junction protein alterations were not 
observed in perforin-deficient mice. Additionally, to investigate the possibility that 
apoptosis is the cause of CNS vascular permeability, active caspase-3 protein levels were 
assessed. These levels did not increase until after peak levels of CNS vascular permeability, 
indicating that apoptosis does not initiate this permeability. In addition, the increase in 
claudin-5 levels serves as evidence that CECs were viable during peak permeability and not 
undergoing apoptosis (Suidan et al., 2008). 
A putative mechanism of CD8+ T cell-mediated CNS vascular permeability is induction of 
vascular endothelial growth factor (VEGF) in the CNS. This cytokine has a highly vascular-
permeating effect, and, along with its receptors, undergoes a change in expression following 
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insult to the CNS (Deininger et al., 2003; Ferrara et al., 2003; Krum & Khaibullina, 2003; 
Krum et al., 2008;  Lafuente et al., 2006; Proescholdt et al., 1999; Proescholdt, et al., 2002; 
Senger et al., 1983; Su et al., 2006; Srikiatkhachorn et al., 2007; Zhang et al., 2000). Because 
signal transduction through binding of VEGF to its receptor, fetal liver kinase-1 (flk-1), leads 
to vascular permeability, there may be an important role for this cytokine in disruption of 
the BBB during neuroinflammatory conditions (Ferrara et al., 2003). Through analysis of 
VEGF protein levels and FITC albumin-leakage into the brain, it was found that both VEGF 
protein and phosphorylation of flk-1 were significantly increased following administration 
of VP2 peptide. Coinciding with these increases was an increase in leakage of FITC-albumin, 
and thus CNS vascular permeability. During this permeability, in situ hybridization 
revealed that the major source of VEGF expression was neurons. Confocal microscopy 
further confirmed this by showing that immunostaining of the neuronal marker NeuN 
colocalizes VEGF cytokine (Suidan et al., 2010). However, since VEGF is not exclusively 
expressed by neurons clinically and in other model systems, alternative cell types, such as 
GR-1+ neutrophils, may also contribute to BBB disruption through a VEGF dependant 
mechanism. 
Since it has been demonstrated that neuronal expression of VEGF occurred simultaneously 
with CD8 T cell-mediated CNS vascular permeability, VEGF had the potential to be a viable 
therapeutic target in neurological diseases such as AHLE. To investigate this possibility, 
Suidan et al administered the neuropilin-1 inhibitor, ATWLPPR, to 7-day TMEV-infected 
C57BL/6 mice given VP2121-130 peptide or mock E7 peptide. Neuropilin-1 is a coreceptor for 
VEGF and has been shown to enhance processes mediated by the VEGF receptor flk-1 
(Soker et al., 1998). Through analysis of FITC-albumin leakage into the brain, it was found 
that inhibition of neuropilin-1 with high doses of ATWLPPR VEGF inhibitor resulted in 
decreased CNS vascular permeability when compared to mice treated with PBS or 
scrambled RAPTLWP peptide. Furthermore, there was no significant difference between 
mice treated with VEGF inhibitor and mice treated with mock E7 peptide (Suidan et al., 
2010). As previously reported using the PIFS model, degradation of the tight junction 
protein occludin occurs prior to CNS vascular permeability (Suidan et al., 2008). However, 
when mice were treated with ATWLPPR neuropilin-1 inhibitor, occludin protein levels were 
preserved, likely contributing to the maintenance of an impermeable BBB. Therefore, 
inhibition of VEGF-mediated pathways may serve as a strong therapeutic strategy for the 
treatment of neurological diseases characterized by BBB disruption. 
The observation that high neuronal VEGF expression coincided with BBB disruption 
prompts the question of to what extent CNS-infiltrating CD8 T cells could actively engage 
Theiler’s virus-infected neurons. This area of research has been controversial since neurons 
express little or no detectable levels of MHC class I (Corriveau et al., 1998; Horwitz et al., 
1999; Joly et al., 1991; Neumann, et al., 1995; Rall et al., 1995). To address this controversy, 
GFP+ CD8+ cells were adoptively transferred to C57BL/6 mice, and it was found that these 
cells were highly specific for the Db:VP2121-130 epitope. The next major question is which cell 
types are potential targets for these cells. Confocal microscopy revealed that TMEV protein 
translation occurred in the hippocampus, striatum, hypothalamus, and cortex. Positive 
staining with the neuronal marker NeuN revealed that neurons were the main cell type 
translating virus protein. Furthermore, adoptively transferred GFP+ CD8+ cells were found 
in close proximity to TMEV infected neurons and their processes. (McDole et al., 2010). The 
finding that CD8 T cells engage neurons, as shown in Figure 9, also reveals a possible 
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mechanism by which axonal and neuronal damage could take place in neuroinflammatory 
diseases such as AHLE and ADEM.  
 
 
Fig. 9. CD8 T cells form immune synapses with target neurons. Both CD8 protein (A and E) 
and T cell receptor (B and F) polarized toward neurons (C and G) are highly indicative of an 
immune synapse. Merged images are shown (D and H). For A–H, results are representative 
of an analysis of eight mice. All microscopy was performed on hippocampus. Scale bars: 10 
μm (This figure was reproduced from McDole, J.R., S.C. Danzer, et al. (2010). Rapid 
formation of extended processes and engagement of theiler's virus-infected neurons by 
CNS-infiltrating CD8 T cells. The American Journal of Pathology 177(4): 1823-1833. Permission 
was granted by Elsevier). 
It is apparent that CD8 T cells and expression of VEGF contribute to BBB disruption in the 
PIFS model. However, it is possible that the NVU or other immune cell types, such as GR-1+ 
neutrophils, may also contribute to disruption of the BBB in accordance with previously 
published work with the LCMV models of BBB disruption highlighted above. These 
potential mechanisms of virus induced vascular permeability are illustrated in Figure 10. 
Traditional methods of neutrophil depletion, such as those used in the BBB studies of 
LCMV, employ the anti-GR-1 monoclonal antibody RB6-8C5. These studies conclude that 
neutrophils are the critical blood-derived cell type promoting BBB disruption (Kim et al., 
2009). However, RB6-8C5 has been shown to bind to both Ly-6G on neutrophils and Ly-6C 
on lymphocytes and monocytes. Therefore, it is possible that GR-1-specific Ab depletion 
could also remove large numbers of activated CD8 T cells in addition to neutrophils. To 
address this controversy and determine whether CD8 T cells cause BBB disruption without 
the contribution of neutrophils, we have recently employed the TMEV model and used both 
the RB6-8C5 mAb and the Ly-6G-specific mAb 1A8 to deplete neutrophils in vivo. Ablation 
of epitope-specific CD8 T cells was seen in 7-day TMEV infected mice treated with RB6-8C5 
but not those treated with 1A8 or normal rat serum. Therefore, the Ly-6G-specific mAb 1A8 
is more selective for neutrophils in accordance with published results (Daley et al., 2008; 
Dunay et al., 2010). Additionally, anti-GR-1 depletion was shown to preserve motor 
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function, as shown through assessment of the mice on a Rotamex Rotarod, and to reduce 
CNS vascular permeability as demonstrated by assaying FITC-albumin leakage into the 
CNS (data not shown). However, because 1A8 treatment somewhat reduced the levels of 
FITC-albumin leakage into the CNS, there may be a potential role for neutrophils in CD8 T 
cell initiated CNS vascular permeability, and this needs to be investigated further. 
Nevertheless, anti-GR-1 depletion strategies may hold promise as a potential therapeutic 
strategy for neurologic disorders characterized by altered permeability of the BBB. 
 
 
 
Fig. 10. BBB disruption in the PIFS model is induced through intravenous injection of VP2121-
130 peptide at 7 days post TMEV infection. At 7 days post TMEV infection, the CNS 
infiltrating Db:VP2121-130 specific CD8 T cell response peaks.  Administration of VP2121-130 
peptide results in heightened activation of expanded CNS infiltrating Db:VP2121-130 specific 
CD8 T cells interacting with Db class I expressing cells, which could include neurons, 
astrocytes, cerebral endothelial cells, pericytes and microglia. Our central hypothesis (1.) is 
that CD8 T cells engage neurons to promote upregulation of VEGF. Our alternative 
hypothesis (2.) is that CD8 T cells engage a different CNS cell type that results in BBB 
disruption and vascular permeability that is dependent or independent of neuronal VEGF. 
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10. Summary of the experimental model systems to illustrate the contribution 
of immune cells in BBB disruption 
The EAE, LPS, and virus induced CNS vascular permeability model systems have enabled 
an understanding of how immune cells affect and alter CNS cell types of the neurovascular 
unit and ensuing BBB disruption. A defined role for CD4 T cells has been put forth through 
the EAE model, which also demonstrates that astrocyte-derived VEGF and IL-17 cause 
decreases in the tight junction proteins claudin-5 and occludin. The LPS model has 
portrayed a role for TNFǂ, activated microglia, and MMPs in BBB disruption. Similar to the 
EAE model, occludin has also been shown to be decreased in this model. However, claudin-
3 and claudin-5 were found to be increased, and this coincided with BBB disruption. The 
virus induced models of vascular permeability have demonstrated a role for neutrophils, 
CD8 T cells, and VEGF. The LCMV model demonstrates an essential role for CD8 T cells in 
lethality, but puts emphasis on the fact that these cells may primarily serve to attract other 
effector populations, such as GR-1+ neutrophils. The PIFS model, which has the advantage 
of being inducible through the administration of an antigen peptide, also validates a role for 
CD8 T cells in contributing to CNS vascular permeability. Similar to the LPS model, the PIFS 
model also reveals a decrease in occludin and an increase in claudin-5, both of which are 
dependent on perforin expression. In accordance with the EAE model, VEGF is also shown 
to play a major role in BBB disruption. Furthermore, time course experiments using this 
model enabled the discovery of the order of events involved in BBB disruption, showing 
that astrocyte activation and degradation of occludin occur prior to CNS vascular 
permeability and motor deficits. Taken together, these models have put forward a defined 
role for neutrophils, CD4 and CD8 T cells, and VEGF in BBB disruption. This knowledge 
provides important information on the extent inflammatory immune cells contribute to CNS 
vascular permeability in diseases such as ADEM and AHLE. Therefore, continued efforts to 
control inflammation and dampen VEGF-mediated vascular permeability are important 
therapeutic approaches for  treatment of these conditions. 
11. Conclusion 
Knowledge of the extent inflammatory immune cells contribute to disruption of the BBB is 
essential in order to develop treatments for ADEM and AHLE, two diseases that currently 
have no standard therapies and whose etiology is still not well understood. These potential 
therapies could also extend beyond ADEM and AHLE to other diseases characterized by 
increased BBB disruption, such as multiple sclerosis, viral hemorrhagic fevers, and cerebral 
malaria. The current experimental model systems available to address the contribution of 
inflammatory cells in BBB disruption open the door to several potential therapies. For 
example, it is apparent from both the EAE model and the PIFS model that targeting VEGF 
and inhibiting VEGF-mediated pathways may help ameliorate BBB disruption. In support of 
this therapeutic approach, we have determined that inhibition of neuropilin-1, a co-receptor 
for VEGF, decreased CNS vascular permeability (Suidan 2010). It is also evident through the 
EAE model that targeting the signaling pathways of occludin, the mechanisms of 
proinflammatory cytokines such as IL-17, and the tight junction architecture may provide 
avenues for potential therapeutic approaches. Results obtained from the LPS model 
demonstrate that directing research at MMP inhibitors and targeting microglia to potentially 
stop the production of inflammatory factors may also be valuable tools. The LCMV model 
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portrays a need to investigate reducing myelomonocytic activation or targeting CTL 
chemotactic mechanisms that recruit myelomonocytic cells as a potential means of 
treatment. Finally, the PIFS model demonstrates that strategies that target CD8 T cells and 
VEGF cytokine may hold promise as potential therapies to ameliorate severe BBB 
disruption. Future research in these areas as well as in additional mechanisms by which 
immune cells cause BBB disruption will aid in the development of more specific therapies to 
address these devastating immune-mediated neurological disorders. 
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